Understanding the role of sclerostin in bone remodeling led to the development and subsequent approval of romosozumab — a humanized monoclonal anti-sclerostin antibody — for the treatment of osteoporosis in postmenopausal women at high risk of fractures, by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2019 (24). This evidence concerns the gene SOST and osteoporosis.